{"url_path":"/sec/aptof/8-k/2026-07-01/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-01","source_url":"https://www.sec.gov/Archives/edgar/data/882361/0001193125-26-291114-index.html","accession_number":"0001193125-26-291114","cik":"0000882361","ticker":"APTOF","issuer_name":"Aptose Biosciences Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/882361/0001193125-26-291114-index.html","primary_entity_key":"0000882361","primary_entity_name":"Aptose Biosciences Inc."},"word_count":144,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit\n\nNumber\n\n  \n\nDescription of Exhibit\n\n 2.1\n  \n[Arrangement Agreement, dated February 23, 2026 (filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K) filed February 24, 2026 and incorporated herein by reference)](http://www.sec.gov/Archives/edgar/data/882361/000119312526064847/d70162dex21.htm)\n\n99.1\n  \n[Opinion of Locust Walk Securities, LLC (incorporated herein by reference to Appendix E of the Company’s Proxy Statement contained in the definitive Schedule 14A filed February 24, 2026)](http://www.sec.gov/Archives/edgar/data/882361/000119312526064774/d84625ddefm14a.htm#tx84625_112)\n\n99.2\n  \n[Press Release dated June 30, 2026](d161768dex992.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n3\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nAptose Biosciences Inc.\n\nDate: June 30, 2026\n \n\n \nBy:\n \n\n/s/ William G. Rice, Ph.D.\n\n \n\n \n\n \nWilliam G. Rice, Ph.D.\n\n \n\n \n\n \nChairman, President, and Chief Executive Officer"}